Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-134449

Published: 2020

Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136136

Published: 2020

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Demi Niforos, MS, Mark Kowalski, MD, PhD, Linda M Bavisotto, MD, Jun Kawashima, MD, Susie Jun, MD, PhD, Helen Collins, MD, Srinivasan Ramanathan, PhD

Blood (2013) 122 (21): 1590.

https://doi.org/10.1182/blood.V122.21.1590.1590

Published: 2013

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 178.

https://doi.org/10.1182/blood.V120.21.178.178

Published: 2012

NARROW

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only